Abstract
[Objective] To clarify the pharmacokinetic profile of prulifloxacin (PUFX) in patients undergoing hemodialysis (HD). [Methods] The plasma concentration of ulifloxacin (UFX), the active metabolite of PUFX, was measured in 8 HD patients after single or multiple once-daily oral administration of prulifloxacin (264.2mg). HD was performed with a blood flow of 180~290mL/min from 2 to 6h after dosing following a single administration and on alternate days for patients receiving successive administrations. [Results] In single administration, the biological half life in blood and the area under the curve for UFX were 15.4±4.5hr and 12.9±6.7μg•hr/mL, respectively. In daily administration, the plasma concentration of UFX on day3 was higher than that on day1 pre HD and post HD, but there was no significant difference (pre HD, p=0.2180 ; post HD, p=0.1635). There were no apparent side effects during the study period. [Conclusion] The pharmacokinetic profile of PUFX suggested that the appropriate dosage of PUFX was 132.1mg once a day and the HD procedure was performed from 4 to 6hr after administration of PUFX in HD patients.
